Moderna, Inc. (MRNA) Stock: Jefferies Sees $54B Peak Sales for Cancer Therapy 

TLDR Moderna shares plunged 24.56% despite positive Phase III melanoma trial results. Jefferies models $54 billion in global peak sales for Moderna’s cancer therapy. The melanoma study met recurrence-free and distant metastasis-free endpoints. Jefferies raised Moderna’s price target to $170 and upgraded shares to Neutral. Upcoming detailed trial data could shape confidence in Moderna’s oncology [...]

The post Moderna, Inc. (MRNA) Stock: Jefferies Sees $54B Peak Sales for Cancer Therapy  appeared first on Blockonomi.